A systematic review and meta-analysis of randomized controlled trials of the effect of barley β-glucan on LDL-C, non-HDL-C and apoB for cardiovascular disease risk reductioni-iv
Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S, Jovanovski E, Au-Yeung F, et al.
Published in Eur J Clin Nutr, Vol. 70 (11), pp. 1239-1245
Methodology
Systematic review and meta-analysis of randomised controlled trials of at least 3 weeks assessing barley beta-glucan-enriched diets against control diets.
Key Findings
14 trials (n=615). A median 6.5 g/day of barley beta-glucan over a median 4 weeks lowered LDL cholesterol by 0.25 mmol/L (95% CI 0.20 to 0.30) and non-HDL cholesterol by 0.31 mmol/L; apoB did not change significantly.
Conclusions
Barley beta-glucan lowers LDL and non-HDL cholesterol; barley foods may help with cardiovascular risk targets.
Limitations
Short trials (median 4 weeks), higher doses than the 3 g/day usually advised, considerable heterogeneity for non-HDL cholesterol (I2=98%).
Supplements Studied
significantly reduced LDL-C
Outcomes Measured
significantly reduced LDL-C
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.